Friday, April 22, 2016 9:28:51 PM
Intrexon Provides Update on Recent Stock Trading Activity
PR NEWSWIRE 7:15 AM ET 4/22/2016
Symbol Last Price Change
XON 27.1 -9.73 (-26.42%)
QUOTES AS OF 04:00:41 PM ET 04/21/2016
GERMANTOWN, Md. , April 22, 2016 /PRNewswire/ -- Intrexon Corporation(XON) , a leader in synthetic biology, provided an update to its shareholders regarding recent trading activity in the company's common stock. On Thursday, April 21, 2016, a materially false and misleading report regarding the company, its subsidiaries and its chairman and CEO was published on Seeking Alpha, a financial blog.
Intrexon Corporation logo
Intrexon (XON) does not, as a general matter, respond to blog posts, investor reports or analyst communications. In this case, however, Intrexon(XON) is providing this update given the inaccuracy of the report's content, the stated intent of the publisher to issue several more spurious reports in the coming days, and information received last night regarding the erroneous publication.
Yesterday evening, Intrexon(XON) received a draft report, dated December 2015, which contained similarly inaccurate claims and strikingly similar language, in some parts identical words, to that used in yesterday's report. Moreover, Intrexon(XON) received information that the source of the report was a particular hedge fund seeking to discredit Intrexon(XON). The hedge fund, according to our information, desired to take a short position in the company's stock, was seeking a willing publisher of its report on the company, and intended to benefit from trading activity caused thereby.
Based on this information, Intrexon(XON) believes that it is the target of a campaign to manipulate trading in the company's securities, interfere with the company's business operations, and destroy the reputation of the company and its chairman and CEO. Intrexon(XON), with the advice of counsel, is taking appropriate steps in light of these developments. In the meantime, we wish to assure our investors, collaboration partners, and employees that the company remains dedicated to advancing our business and to generating value for our shareholders.
Recent PGEN News
- Precigen to Participate in the 2024 Cantor Global Healthcare Conference • PR Newswire (US) • 09/16/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:00:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:25:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:19:00 PM
- Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates • PR Newswire (US) • 08/14/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 09:09:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 01:04:35 PM
- Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th • PR Newswire (US) • 08/09/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:19:45 PM
- Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock • PR Newswire (US) • 08/08/2024 01:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 08:46:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:13:44 PM
- Precigen Announces Proposed $30 Million Public Offering of Common Stock • PR Newswire (US) • 08/06/2024 08:04:00 PM
- Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:21:47 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:20:43 PM
- Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch • PR Newswire (US) • 07/23/2024 12:01:00 PM
- Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response • PR Newswire (US) • 06/03/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:06:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:04:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:03:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:00:45 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/28/2024 08:48:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/28/2024 08:44:39 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM